Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.71), $0.03 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $250 thousand.

As of March 31, 2017, Syndax had cash, cash equivalents and short-term investments of $92.8 million and 18,244,917 shares issued and outstanding.

Financial Guidance

Today the Company provided operating expense guidance for the second quarter and full year 2017. For the second quarter and full year 2017, research and development expenses are expected to be $11.0 – $13.0 million and $52.0 - $57.0 million, respectively, and total operating expenses are expected to be $15.0 – $17.0 million and $68.0 - $73.0, respectively.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.